Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

71 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-31

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease, have a 20- to 50-fold higher risk of developing primary liver cancer (PLC), such as hepatocellular carcinoma (HCC), in both cirrhotic and non-cirrhotic livers, highlighting AATD as a potential oncogenic factor. Therefore, our aim is to evaluate the association between AATD and HCC in patients with a non-cirrhotic liver and no known predisposition

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease

NCT03307408

Hepatocellular Carcinoma

UNKNOWN

Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment

NCT01492127

Hepatocellular Carcinoma Cirrhosis

UNKNOWN NA

Liver Disease in Adults With Alpha-1 AT Deficiency

NCT01455298

Alpha-1 AT Deficiency

COMPLETED NA

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

NCT03894917

Carcinoma, Hepatocellular

RECRUITING

Early Detection of Alcoholic Liver Disease

NCT04070508

Alcoholic Liver Disease Alcoholic Fibrosis of Liver Alcoholic Cirrhosis +5 more

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The two most common pathogenic AATD variants, PiS and PiZ, will be identified using the multiplex digital PCR (dPCR) system in a French cohort of 71 patients who developed HCC in a non-cirrhotic liver without known risk factors for HCC

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retrospective Cohort of Patients Diagnosed With HCC on Non-Cirrhotic Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients Diagnosed with HCC on Non-Cirrhotic Liver

multiplex digital PCR

Intervention Type OTHER

multiplex digital PCR

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

multiplex digital PCR

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult patients (≥18 years of age).
2. Histopathologically confirmed diagnosis of hepatocellular carcinoma (HCC).
3. Normal liver or chronic liver disease with minimal to moderate fibrosis in non-tumoral tissue.
4. Signed informed consent obtained prior to participation.
5. No other known etiology or risk factors for liver disease, including:

* Alcohol-related liver disease
* Metabolic-associated steatohepatitis (MASH)
* Viral hepatitis infections
* Hemochromatosis

Exclusion Criteria

1. Minor patients (\<18 years of age).
2. HCC diagnosis not established according to standard histopathological criteria.
3. Liver with chronic liver disease showing advanced fibrosis in non-tumoral tissue.
4. No signed informed consent prior to participation.
5. Presence of other identified etiologies or known risk factors for liver disease, including:

* Alcohol-related liver disease
* Metabolic-associated steatohepatitis (MASH)
* Viral hepatitis infections
* Hemochromatosi

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No